Home » Medical Devices » Microbial Contract Biomanufacturing Market

Microbial Contract Biomanufacturing Market By Expression System (Bacterial Expression Systems, Yeast Expression Systems, Other Expression Systems); By Biologic (Recombinant Proteins, Enzymes, Plasmid DNA, Antibodies, Others); By Company Size (Small, Mid-sized, Large, Very Large); By End-User (Pharma / Biotech Companies, Academic / Research Institutes) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 41008 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period 2019-2022
Base Year 2023
Forecast Period 2024-2032
Microbial Contract Biomanufacturing market Size 2023 USD 3,301.2 million
Microbial Contract Biomanufacturing market, CAGR 8.3%
Microbial Contract Biomanufacturing market Size 2032 USD 6,812.87 million

Market Overview

The Microbial Contract Biomanufacturing market is projected to grow from USD 3,301.2 million in 2024 to USD 6,812.87 million by 2032, reflecting a compound annual growth rate (CAGR) of 8.3%.

The Microbial Contract Biomanufacturing market is thriving due to increasing demand for biopharmaceuticals such as vaccines, insulin, and monoclonal antibodies. Rapid advancements in microbial fermentation technologies enhance production efficiency and product yield, driving market growth. The trend towards outsourcing by pharmaceutical companies to reduce costs and streamline operations is also significantly contributing to market expansion. Furthermore, the rise in chronic diseases globally necessitates continued development and production of biologics, supporting the growth of microbial contract biomanufacturing services. These factors, combined with the expansion of biotech startups focusing on novel microbial-based products, underscore the dynamic progress in this sector.

The Microbial Contract Biomanufacturing Market is globally diverse, with key players strategically positioned across various regions to leverage local advantages and expand their market reach. AGC Biologics and Ology Bioservices are prominent in North America, capitalizing on advanced biotechnology ecosystems and robust investment in biopharmaceutical R&D. In Europe, Eurogentec and Northway Biotech pharma excel by offering specialized microbial manufacturing services, supported by strong regulatory frameworks and innovation incentives. Stelis Biopharma in Asia and Porton Biopharma in the UK highlight the expansion of microbial biomanufacturing capabilities into emerging markets and established pharmaceutical landscapes, respectively, driving global growth and accessibility in the sector.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Drivers

Expanding Demand for Biologics and Biosimilars:

The pharmaceutical sector is experiencing robust growth in the demand for biologics—highly effective drugs derived from living cells. For example, biosimilars can offer a cost reduction of up to 30% compared to original biologics, offering significant cost savings and broadening patient access to essential medications. Microbial contract biomanufacturing provides a scalable and cost-efficient solution for producing these complex molecules, essential for treating various chronic and rare diseases. Concurrently, the surge in biosimilars and biogeneric drugs, spurred by patent expirations of major biologics, further propels this market. These alternatives, mirroring their brand-name counterparts, offer significant cost savings and broaden patient access to essential medications.

Technological Enhancements in Microbial Production:

Recent technological advances in synthetic biology and metabolic engineering have significantly improved microbial fermentation, optimizing the production of complex biochemicals. For instance, some engineered strains have shown a 50% increase in the production yield of certain pharmaceuticals. These advancements allow for the modification of microbial hosts to enhance yield, purity, and efficiency of biomanufacturing processes. The capabilities of microbial systems to produce diverse therapeutic products—including enzymes, vaccines, and antibodies—make them particularly valuable to the pharmaceutical industry, driving forward the capabilities and adoption of microbial contract biomanufacturing.

Strategic Advantages of Contract Manufacturing:

Pharmaceutical and biotech companies are increasingly partnering with microbial contract manufacturing organizations (CMOs) to capitalize on their expertise and scalable processes. For instance, partnering with CMOs has been shown to reduce the time to market for new drugs by up to 18 months. This collaboration enables drug developers to focus on core competencies such as R&D and market strategy while relying on CMOs for operational efficiencies in the production of drugs. This not only speeds up the time to market but also manages cost pressures effectively, making it a strategic imperative in today’s competitive landscape.

Market Growth Through Diverse Applications:

The scope of microbial contract biomanufacturing is broadening beyond pharmaceuticals, encompassing sectors like industrial enzymes and biofuels, which further diversifies the market’s potential. Increased investment from venture capitals and pharmaceutical giants in biologics underscores the expanding role of microbial biomanufacturing. Additionally, as healthcare systems globally push for cost containment, microbial biomanufacturing stands out as a method to reduce overall expenses, thereby facilitating the production of more affordable therapeutic solutions. These factors collectively forecast a promising growth trajectory for the microbial contract biomanufacturing market.

Market Trends

Enhancing Production Efficiency through Technological Integration and Continuous Processes:

The Microbial Contract Biomanufacturing Market is experiencing a significant shift towards continuous manufacturing, marked by a transition from traditional batch processes to uninterrupted production. For instance, continuous manufacturing has been shown to reduce production cycle times by up to 80% and increase overall efficiency by 40%. This change not only minimizes downtime but also enhances overall efficiency and throughput, allowing manufacturers to respond more swiftly to market demands. Concurrently, the integration of advanced analytics and process control technologies is revolutionizing microbial fermentation. These technologies enable real-time monitoring and adjustments, ensuring optimal process conditions, which significantly improve product yield and consistency. For example, advanced sensors and control systems have led to a 25% improvement in the consistency of bioproducts.

Broadening Applications and Advancing Sustainability in Biomanufacturing:

The application spectrum of microbial contract biomanufacturing is expanding beyond traditional pharmaceuticals to include sectors such as nutraceuticals, cosmetics, and agriculture. For instance, the use of microbial fermentation in the production of nutraceuticals like omega-3 fatty acids has increased by 30% in the last two years. This diversification is driven by the versatility and adaptability of microbial processes to various product demands, offering substantial growth opportunities for the industry. In parallel, there is a growing emphasis on sustainability within the sector. Biomanufacturers are increasingly adopting practices that reduce environmental impact, such as utilizing renewable feedstocks and optimizing resource efficiency. For example, the adoption of green chemistry principles in biomanufacturing has led to a 20% reduction in waste generation and a 15% decrease in energy consumption.

Market Challenges Analysis

Navigating Regulatory Complexities and Intellectual Property Challenges:

The Microbial Contract Biomanufacturing Market contends with a highly complex regulatory environment that necessitates strict compliance to ensure the safety and efficacy of biologics. Navigating these regulatory waters requires significant time and financial resources, often constraining the speed at which new products can reach the market. In parallel, intellectual property (IP) protection remains a critical concern for biopharmaceutical companies outsourcing to Contract Manufacturing Organizations (CMOs). Establishing robust contractual agreements and clear risk-sharing models is crucial to safeguard proprietary technologies and foster trust between clients and CMOs, ensuring that sensitive information and process innovations are adequately protected.

Operational and Market Dynamics Challenges:

Scaling microbial fermentation processes from the lab to commercial production presents distinct challenges, particularly in maintaining consistency and optimizing yields across larger batches. This scale-up often requires sophisticated process control and deep technical expertise, areas where CMOs must continuously invest to support seamless transitions and high-quality outputs. Additionally, the sector is experiencing intensified competition and capacity constraints, compelling CMOs to expand their facilities and innovate in process efficiencies to meet the increasing demand. Alongside these issues, the industry faces ongoing challenges in workforce development, needing skilled professionals in microbiology and bioprocessing to support its growth and innovation aspirations.

Market Segmentation Analysis:

By Expression System:

The Microbial Contract Biomanufacturing Market is segmented by expression systems, with each offering unique advantages for specific biologic productions. Bacterial Expression Systems are highly favored for their rapid growth rates and high yields, making them ideal for large-scale production of proteins and enzymes. Yeast Expression Systems provide a good balance between the simplicity of bacterial systems and the complex post-translational modifications offered by eukaryotic systems. They are particularly useful for producing recombinant proteins and vaccines. Other Expression Systems, including fungal and algal, are explored for their unique properties that can be advantageous in producing certain types of biologics, such as complex protein structures not feasible with more conventional systems.

By Biologic:

In the Microbial Contract Biomanufacturing Market, the diversity of biologics produced reflects the versatility of microbial systems. Recombinant Proteins and Enzymes are predominantly manufactured using microbial systems due to the straightforward nature of the organisms and the ease of genetic manipulation. Plasmid DNA, a critical component for gene therapies and vaccines, benefits from the rapid replication and high yields possible in microbial systems. Antibodies and other complex molecules are increasingly being produced through advanced microbial systems that can be engineered to perform necessary post-translational modifications, enhancing their therapeutic efficacy and market applicability.

Segments:

Based on Expression System:

  • Bacterial Expression Systems
  • Yeast Expression Systems
  • Other Expression Systems

Based on Biologic:

  • Recombinant Proteins
  • Enzymes
  • Plasmid DNA
  • Antibodies
  • Others

Based on Company Size:

  • Small
  • Mid-sized
  • Large
  • Very Large

Based on End-User:

  • Pharma / Biotech Companies
  • Academic / Research Institutes

Based on the Geography:

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Regional Analysis

North America

North America holds a significant share of the microbial contract biomanufacturing market, driven by the region’s well-established biopharmaceutical industry and a strong focus on outsourcing biomanufacturing activities. The United States, in particular, is a major contributor to the North American market, accounting for approximately 40% of the global market share. The presence of leading contract manufacturing organizations (CMOs), coupled with a robust regulatory environment and a skilled workforce, has fueled the demand for microbial contract biomanufacturing services in this region.

Europe

Europe represents another prominent market for microbial contract biomanufacturing, owing to its advanced biotechnology sector and a growing emphasis on cost-effective biomanufacturing solutions. Countries such as Germany, the United Kingdom, and France have been at the forefront of adopting outsourced microbial biomanufacturing services to support the development and production of biopharmaceuticals, enzymes, and other microbial-derived products. The European microbial contract biomanufacturing market currently holds a market share of around 28%, driven by the region’s commitment to innovation and the development of cutting-edge biotechnologies.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key Player Analysis

  • AGC Biologics
  • Aldevron
  • BioVectra
  • EirGenix
  • Etinpro
  • Eurogentec
  • Northway Biotechpharma
  • Ology Bioservices
  • Porton Biopharma
  • Stelis Biopharma

Competitive Analysis

The competitive landscape of the Microbial Contract Biomanufacturing Market is dynamic, with key players like AGC Biologics, Eurogentec, and Ology Bioservices driving innovation and expansion. AGC Biologics leverages its global presence and technological expertise to offer comprehensive biomanufacturing solutions, which helps it maintain a competitive edge. Eurogentec, known for its strong focus on quality and regulatory compliance, excels in producing complex biologics, catering particularly to the European market. Ology Bioservices distinguishes itself through its advanced facilities in the U.S., focusing on government contracts and complex biological agents. Northway Biotechpharma and BioVectra extend their reach by specializing in both small and large-scale production capacities, appealing to a wide range of clients from startups to large pharmaceutical companies. These companies continuously invest in technological advancements and capacity expansions to meet the growing demands of the biopharmaceutical sector, enhancing their competitiveness.

Recent Developments

  • In January 2024, Scorpius Biomanufacturing, a subsidiary of NightHawk Biosciences had secured a project supporting a preclinical program for a US based biotechnology company, with an initial value exceeding USD 1 million and the potential to grow significantly over the next two years. The project focuses on Scorpius analytical and process development labs, emphasizing expertise in microbial fermentation.
  • In June 2023, Culture Biosciences and Cytiva entered into a partnership agreement to enhance innovation in upstream bioprocessing, offering advanced scale-up capabilities to customers. The partnership focused on integration of Culture Biosciences’ 250 mL bioreactor into Cytiva’s Bioreactor Scaler tool, facilitating seamless scaling between development and manufacturing.

Market Concentration & Characteristics

The Microbial Contract Biomanufacturing Market exhibits a moderate to high level of market concentration, characterized by a blend of well-established players and a few emerging companies making significant strides. Leaders like AGC Biologics, Eurogentec, and Ology Bioservices dominate the market, offering extensive capabilities from development to large-scale manufacturing, backed by robust compliance with stringent regulatory standards. This market is marked by intense competition and innovation, where key players invest heavily in cutting-edge technologies and expansions to cater to the growing demands for biologics production. The presence of specialized small and mid-sized enterprises that offer niche services also enriches the market’s diversity. Overall, the industry’s growth is propelled by the increasing outsourcing of biomanufacturing by pharmaceutical companies, driven by the need for expertise in complex biologic production and cost-efficiency in operations. This competitive environment encourages continual advancements in microbial fermentation technology and expansion into global markets.

Report Coverage

The research report offers an in-depth analysis based on Expression System, Biologic, Company Size, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

  1. Continued growth in demand for biologics will drive expansion in microbial contract biomanufacturing capacities.
  2. Increased investments in biomanufacturing facilities to support the production of biosimilars and biogeneric drugs.
  3. Advancements in microbial fermentation technologies will enhance production efficiency and yields.
  4. Adoption of single-use technologies will continue to rise, reducing contamination risks and operational costs.
  5. Expansion of services by microbial CMOs into new regions to better serve a global client base.
  6. Greater emphasis on sustainable practices and reduction of environmental impact in biomanufacturing processes.
  7. Enhanced focus on developing and commercializing next-generation biologics through microbial systems.
  8. Integration of advanced analytics and automation to improve process control and scalability.
  9. Strengthening of collaborations between biopharmaceutical companies and CMOs to facilitate faster drug development cycles.
  10. Continuous updating and compliance with evolving regulatory guidelines for biomanufacturing across global markets.

1. Introduction

1.1. Report Description

1.2. Purpose of the Report

1.3. USP & Key Offerings

1.4. Key Benefits for Stakeholders

1.5. Target Audience

1.6. Report Scope

1.7. Regional Scope

2. Scope and Methodology

2.1. Objectives of the Study

2.2. Stakeholders

2.3. Data Sources

2.3.1. Primary Sources

2.3.2. Secondary Sources

2.4. Market Estimation

2.4.1. Bottom-Up Approach

2.4.2. Top-Down Approach

2.5. Forecasting Methodology

3. Executive Summary

4. Introduction

4.1. Overview

4.2. Key Industry Trends

5. Global Microbial Contract Biomanufacturing Market

5.1. Market Overview

5.2. Market Performance

5.3. Impact of COVID-19

5.4. Market Forecast

6. Market Breakup by Expression System

6.1. Bacterial Expression Systems

6.1.1. Market Trends

6.1.2. Market Forecast

6.1.3. Revenue Share

6.1.4. Revenue Growth Opportunity

6.2. Yeast Expression Systems

6.2.1. Market Trends

6.2.2. Market Forecast

6.2.3. Revenue Share

6.2.4. Revenue Growth Opportunity

6.3. Other Expression Systems

6.3.1. Market Trends

6.3.2. Market Forecast

6.3.3. Revenue Share

6.3.4. Revenue Growth Opportunity

7. Market Breakup by Biologic

7.1. Recombinant Proteins

7.1.1. Market Trends

7.1.2. Market Forecast

7.1.3. Revenue Share

7.1.4. Revenue Growth Opportunity

7.2. Enzymes

7.2.1. Market Trends

7.2.2. Market Forecast

7.2.3. Revenue Share

7.2.4. Revenue Growth Opportunity

7.3. Plasmid DNA

7.3.1. Market Trends

7.3.2. Market Forecast

7.3.3. Revenue Share

7.3.4. Revenue Growth Opportunity

7.4. Antibodies

7.4.1. Market Trends

7.4.2. Market Forecast

7.4.3. Revenue Share

7.4.4. Revenue Growth Opportunity

7.5. Others

7.5.1. Market Trends

7.5.2. Market Forecast

7.5.3. Revenue Share

7.5.4. Revenue Growth Opportunity

8. Market Breakup by Company Size

8.1. Small

8.1.1. Market Trends

8.1.2. Market Forecast

8.1.3. Revenue Share

8.1.4. Revenue Growth Opportunity

8.2. Mid-sized

8.2.1. Market Trends

8.2.2. Market Forecast

8.2.3. Revenue Share

8.2.4. Revenue Growth Opportunity

8.3. Large

8.3.1. Market Trends

8.3.2. Market Forecast

8.3.3. Revenue Share

8.3.4. Revenue Growth Opportunity

8.4. Very Large

8.4.1. Market Trends

8.4.2. Market Forecast

8.4.3. Revenue Share

8.4.4. Revenue Growth Opportunity

9. Market Breakup by End-User

9.1. Pharma / Biotech Companies

9.1.1. Market Trends

9.1.2. Market Forecast

9.1.3. Revenue Share

9.1.4. Revenue Growth Opportunity

9.2. Academic / Research Institutes

9.2.1. Market Trends

9.2.2. Market Forecast

9.2.3. Revenue Share

9.2.4. Revenue Growth Opportunity

10. Market Breakup by Region

10.1. North America

10.1.1. United States

10.1.1.1. Market Trends

10.1.1.2. Market Forecast

10.1.2. Canada

10.1.2.1. Market Trends

10.1.2.2. Market Forecast

10.2. Asia-Pacific

10.2.1. China

10.2.2. Japan

10.2.3. India

10.2.4. South Korea

10.2.5. Australia

10.2.6. Indonesia

10.2.7. Others

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. United Kingdom

10.3.4. Italy

10.3.5. Spain

10.3.6. Russia

10.3.7. Others

10.4. Latin America

10.4.1. Brazil

10.4.2. Mexico

10.4.3. Others

10.5. Middle East and Africa

10.5.1. Market Trends

10.5.2. Market Breakup by Country

10.5.3. Market Forecast

11. SWOT Analysis

11.1. Overview

11.2. Strengths

11.3. Weaknesses

11.4. Opportunities

11.5. Threats

12. Value Chain Analysis

13. Porters Five Forces Analysis

13.1. Overview

13.2. Bargaining Power of Buyers

13.3. Bargaining Power of Suppliers

13.4. Degree of Competition

13.5. Threat of New Entrants

13.6. Threat of Substitutes

14. Price Analysis

15. Competitive Landscape

15.1. Market Structure

15.2. Key Players

15.3. Profiles of Key Players

15.3.1. AGC Biologics

15.3.1.1. Company Overview

15.3.1.2. Product Portfolio

15.3.1.3. Financials

15.3.1.4. SWOT Analysis

15.3.2. Aldevron

15.3.3. BioVectra

15.3.4. EirGenix

15.3.5. Etinpro

15.3.6. Eurogentec

15.3.7. Northway Biotechpharma

15.3.8. Ology Bioservices

15.3.9. Porton Biopharma

15.3.10. Stelis Biopharma

16. Research Methodology

Frequently Asked Questions:

What is the current size of the Microbial Contract Biomanufacturing Market?

The current size of the Microbial Contract Biomanufacturing Market is projected to be USD 3,301.2 million in 2024.

What factors are driving the growth of the Microbial Contract Biomanufacturing Market?

The growth of the Microbial Contract Biomanufacturing Market is driven by the increasing demand for biopharmaceuticals, technological advancements in microbial fermentation, and the rising trend of outsourcing biomanufacturing to reduce costs and enhance efficiency.

What are the key segments within the Microbial Contract Biomanufacturing Market?

Key segments within the Microbial Contract Biomanufacturing Market include expression systems (bacterial, yeast, other), types of biologics (recombinant proteins, enzymes, plasmid DNA, antibodies, others), company size (small, mid-sized, large, very large), and end-users (pharma/biotech companies and academic/research institutes).

What are some challenges faced by the Microbial Contract Biomanufacturing Market?

Challenges in the Microbial Contract Biomanufacturing Market include regulatory complexities, intellectual property concerns, scaling up production, competition and capacity constraints, and the need for a skilled workforce.

Who are the major players in the Microbial Contract Biomanufacturing Market?

Major players in the Microbial Contract Biomanufacturing Market include AGC Biologics, Aldevron, BioVectra, EirGenix, Eurogentec, Northway Biotechpharma, Ology Bioservices, Porton Biopharma, and Stelis Biopharma.

Which segment is leading the market share?

The segment leading the market share in the Microbial Contract Biomanufacturing Market typically involves bacterial expression systems due to their cost-effectiveness, efficiency, and broad applicability in producing a wide range of biopharmaceuticals.

CSF (Cerebrospinal Fluid) Management Market

Published:
Report ID: 12389

Hypodermic Needles Market

Published:
Report ID: 6174

Implantable Infusion Pumps Market

Published:
Report ID: 12455

Medical Robots Market

Published:
Report ID: 42360

Magnetic Resonance Imaging (MRI) Systems Market

Published:
Report ID: 7815

Medical Device Technologies Market

Published:
Report ID: 42130

Transfection Reagents Market

Published:
Report ID: 41609

Intracranial Stents Market

Published:
Report ID: 7131

Hot And Cold Therapy Packs Market

Published:
Report ID: 7187

Digital Therapeutics Market

Published:
Report ID: 5029

Needles Market

Published:
Report ID: 41010

Medical Polymers Market

Published:
Report ID: 40983

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN